Regulatory Story
Go to market news section View chart   Print
Skyepharma PLC  -  SKP   

Miscellaneous re SkyePharma (Jersey) Ltd

Released 15:27 30-Nov-2012

RNS Number : 4803S
Skyepharma PLC
30 November 2012










SkyePharma (Jersey) Limited - Publication of Prospectus


LONDON, UK, 30 November 2012 - SkyePharma PLC (LSE: SKP) announces that SkyePharma (Jersey) Limited has today published a prospectus in order to effect the listing of its £14,764,007 6.5 per cent. Guaranteed Bonds due 2024, which were issued on 24 September 2012.


A copy of the prospectus has been submitted to the National Storage Mechanism and will shortly be available for inspection at:



For further information, please contact:


SkyePharma PLC

Peter Grant, Chief Executive Officer                                                 +44 207 881 0524


FTI Consulting

Jonathan Birt /Julia Phillips/Susan Stuart                                             +44 207 831 3113



About SkyePharma

Using its multiple drug delivery technologies and expertise, SkyePharma creates enhanced versions of pharmaceutical products. The Group receives revenues from thirteen approved products in the areas of inhalation, oral, topical and injectable delivery as well as generating income from the development of further products and technology licenses. The Group's products are marketed throughout the world by leading pharmaceutical companies. For more information, visit



This information is provided by RNS
The company news service from the London Stock Exchange

London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.


Miscellaneous re SkyePharma (Jersey) Ltd - RNS